Population Pharmacokinetic Evaluation of Adlimumab Reveals Patient Factors That Increase Adalimumab Clearance and Shorten Half-Life in Inflammatory Bowel Disease Patients

被引：0
|
作者：
Dotan, Iris
Yanai, Henit
Ron, Yulia
Kariv, Revital
Fishman, Sigal
Yahav, Lior
Ben-Yehoyada, Merav
Santo, Erwin
Mould, Diane R.
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1250
引用
收藏
页码：S243 / S243
页数：1
相关论文
共 17 条
  • [1] Population Pharmacokinetic Evaluation of Infliximab Reveals Patient Factors That Increase Infliximab Clearance and Shorten Half-Life in Inflammatory Bowel Disease Patients
    Dotan, Iris
    Ron, Yulia
    Yanai, Henit
    Becker, Stuart A.
    Fishman, Sigal
    Yahav, Lior
    Ben Yehoyada, Merav
    Mould, Diane R.
    GASTROENTEROLOGY, 2013, 144 (05) : S774 - S774
  • [2] Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
    Dotan, Iris
    Ron, Yulia
    Yanai, Henit
    Becker, Stuart
    Fishman, Sigal
    Yahav, Lior
    Ben Yehoyada, Merav
    Mould, Diane R.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (12) : 2247 - 2259
  • [3] Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease
    Marquez-Megias, Silvia
    Ramon-Lopez, Amelia
    Mas-Serrano, Patricio
    Diaz-Gonzalez, Marcos
    Candela-Boix, Maria Remedios
    Nalda-Molina, Ricardo
    PHARMACEUTICS, 2021, 13 (08)
  • [4] A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
    Brandse, Johannan F.
    Mould, Diane
    Smeekes, Oscar
    Ashruf, YaeL
    Kuin, Sabine
    Strik, Anne
    van den Brink, Gijs R.
    D'Haens, Geert R.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (04) : 650 - 660
  • [5] Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease
    Martinez-Romero, Gregorio J.
    Alvarino, Ana
    Hinojosa, Esther
    Mora, Maria
    Oltra, Lorena
    Maroto, Nuria
    Ferrer, Isabel
    Dolores Hinojosa, Maria
    Hinojosa, Joaquin
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019, 111 (06) : 431 - 436
  • [6] FACTORS INFLUENCING CLEARANCE OF ADALIMUMAB IN PATIENTS WITH CROHN'S DISEASE: A POPULATION PHARMACOKINETIC STUDY
    Berends, Sophie E.
    D'Haens, Geert R.
    Van Selm, Juliet
    Strik, Anne S.
    Lowenberg, Mark
    Ponsioen, Cyriel
    Mathot, Ron
    GASTROENTEROLOGY, 2017, 152 (05) : S392 - S392
  • [7] External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease
    Santacana, Eugenia
    Rodriguez-Alonso, Lorena
    Padulles, Ariadna
    Guardiola, Jordi
    Rodriguez-Moranta, Francisco
    Serra, Katja
    Bas, Jordi
    Morandeira, Francisco
    Colom, Helena
    Padulles, Nuria
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 120 - 129
  • [8] Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease (IBD): Patient factors influencing infliximab pharmacokinetics
    Guardiola, J.
    Rodriguez-Alonso, L.
    Santacana, E.
    Padulles, N.
    Colom, H.
    Padulles, A.
    Arajol, C.
    Ruiz-Cerulla, A.
    Cobo, S.
    Bas, J.
    Climent, J.
    Morandeira, F.
    Rodriguez-Moranta, F.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S306 - S307
  • [9] Utility of "trough levels" adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic model
    Juan, G.
    Alvarino, A.
    Mora, M.
    Oltra, L.
    Maroto, N.
    Ferrer, I.
    Hinojosa, E.
    Hinojosa, M. D.
    Hinojosa, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S363 - S364
  • [10] External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease
    Schraepel, Christina
    Kovar, Lukas
    Selzer, Dominik
    Hofmann, Ute
    Tran, Florian
    Reinisch, Walter
    Schwab, Matthias
    Lehr, Thorsten
    PHARMACEUTICS, 2021, 13 (09)
12